Hepatic MGAT2 expression is increased in MASLD patients, and knockout of Mgat2 reduces fat absorption and increases the secretion of GLP-1 and peptide YY (PYY), which are gut hormones that have beneficial effects on blood glucose and appetite remodeling [181, 182]. This evidence concerns the gene MGAT2 and metabolic dysfunction-associated steatotic liver disease.